Next-Generation in vivo Modeling of Human Cancers

Area of Science:

• Oncology
• Translational Medicine
• Genomics

Background:

• Animal models are fundamental to understanding tumor biology and validating cancer therapies.
• Pre-clinical oncology relies on these models for drug target and biomarker discovery, leading to improved patient care.
• Technological advancements, including genetic engineering and single-cell "omics", offer new potential to enhance pre-clinical model informativeness.

Purpose of the Study:

• To review the current state of animal models for human cancers, with a specific focus on malignant gliomas.
• To discuss how emerging technologies can shape the next generation of pre-clinical cancer models.
• To argue for refining animal models to improve the success rate of translational oncology research.

Main Methods:

• Review of state-of-the-art animal models for human cancers.
• Focused analysis of glioma models in dissecting tumor initiation, cell-of-origin, heterogeneity, and immuno-oncology.
• Discussion of transformative technologies like genetic engineering and single-cell "omics".

Main Results:

• Glioma models are instrumental in understanding tumor initiation, identifying cell-of-origin, characterizing tumor heterogeneity, and evaluating immuno-oncology strategies.
• Technological breakthroughs significantly enhance the informative value of pre-clinical cancer models.
• Refined animal models are essential for successful translation of pre-clinical findings to clinical oncology.

Conclusions:

• Animal models, particularly for malignant gliomas, are vital for advancing cancer research and drug development.
• Integrating advanced technologies like genetic engineering and single-cell "omics" will create more informative and predictive pre-clinical models.
• Improving pre-clinical animal models is key to increasing the success rate of translating research findings into effective cancer patient treatments.